Featured Publications
Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic
Kang J, Wu Y, Rybkin A, Yu Y, Chen L, Zakeri K, McBride S, Riaz N, Tsai C, Gelblum D, Wong R, Sherman E, Pfister D, Lee N. Oropharyngeal Cancer Early Outcomes and Challenges During the COVID-19 Pandemic. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e412. PMCID: PMC8536212, DOI: 10.1016/j.ijrobp.2021.07.1185.Peer-Reviewed Original ResearchDefinitive radiation therapyCOVID cohortRadiation therapyMore patientsAdvanced diseaseMonth outcomesPC cohortNew patientsCurative-intent radiation therapyGrade 3 dysphagiaOropharyngeal cancer outcomesCancer-specific survivalSupportive care needsKaplan-Meier methodLong-term outcomesDiagnosis/treatmentCOVID-19 pandemicMATERIAL/METHODSPerson consultsRT startClinicopathologic factorsOPC patientsHistorical cohortMedian timeEarly outcomesDose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT)
Tsai C, McBride S, Riaz N, Kang J, Spielsinger D, Waldenberg T, Yu Y, Chen L, Zakeri K, Wong R, Dunn L, Sherman E, Lee N. Dose and Volume De-Escalation for Elective Nodal Regions in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer (OPC) Undergoing Curative-Intent Concurrent Chemoradiation (CCRT). International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s142-s143. DOI: 10.1016/j.ijrobp.2021.07.321.Peer-Reviewed Original ResearchConcurrent chemoradiationDe-escalation strategiesOropharyngeal cancerGross diseaseNodal recurrenceDisease recurrenceOPC patientsLevel IbHPV-positive OPC patientsLocoregional recurrence-free survivalElective nodal regionsFavorable locoregional controlFeeding tube dependenceHigh-dose cisplatinPositive oropharyngeal cancerPrimary concurrent chemoradiationRecurrence-free survivalNode-positive neckFeeding tube placementLong-term resultsNode-negative neckDe-escalation approachMATERIAL/METHODSHigh control ratesRadiation treatment plans
2021
The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.
Lee N, Sherman E, Schöder H, McBride S, Yu Y, Kang J, Tsai C, Gelblum D, Boyle J, Singh B, Cohen M, Cracchiolo J, Ganly I, Dunn L, Kriplani A, Fetten J, Michel L, Wong R, Pfister D, Riaz N. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. Journal Of Clinical Oncology 2021, 39: 6019-6019. DOI: 10.1200/jco.2021.39.15_suppl.6019.Peer-Reviewed Original ResearchPositron emission tomographyGrade 1Locoregional controlNodal diseaseOropharyngeal carcinomaOPC patientsGrade 2Primary siteGrade 3 adverse eventsWeight lossDe-escalated patientsGross nodal diseaseRecurrent nodal diseaseResolution of hypoxiaSuccessful salvage surgeryExcellent locoregional controlOverall survival rateSpecific treatment responsesPatient-specific treatment responsesConcurrent chemotherapyDefinitive doseMucositis ratesAdditional therapySalvage surgeryAdverse events